» Articles » PMID: 16818857

Design of Nonpeptidic Topomimetics of Antiangiogenic Proteins with Antitumor Activities

Overview
Specialty Oncology
Date 2006 Jul 5
PMID 16818857
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The inhibition of angiogenesis is a promising avenue for cancer treatment. Although some angiostatic compounds are in the process of development and testing, these often prove ineffective in vivo or have unwanted side effects. We have designed, synthesized, and evaluated a small library of nonpeptidic, calixarene-based protein surface topomimetics that display chemical substituents to approximate the molecular dimensions and amphipathic features (hydrophobic and positively charged residues) of the antiangiogenic peptide anginex, which, like many antiangiogenic proteins, consists primarily of an antiparallel beta-sheet structure as the functional unit. Two of the topomimetics (0118 and 1097) were potent angiogenesis inhibitors in vitro, as determined by endothelial cell proliferation, migration, and chick embryo chorioallantoic membrane assays. Moreover, both compounds were highly effective at inhibiting tumor angiogenesis and growth in two mouse models (MA148 human ovarian carcinoma and B16 murine melanoma). Our results demonstrate the feasibility of designing nonpeptidic protein surface topomimetics as novel pharmaceutical agents for clinical intervention against cancer through angiostatic or other mechanisms.

Citing Articles

Anti-angiogenic therapy as potential treatment for adenomyosis.

Harmsen M, Juffermans L, Kroon M, Griffioen A, Huirne J Angiogenesis. 2025; 28(1):12.

PMID: 39862328 PMC: 11762773. DOI: 10.1007/s10456-024-09960-6.


Recent Advances in Synthesis and Applications of Calixarene Derivatives Endowed with Anticancer Activity.

Wojaczynska E, Ostrowska M, Lower M, Czyzyk N, Jakiela A, Marra A Molecules. 2024; 29(17).

PMID: 39275088 PMC: 11397654. DOI: 10.3390/molecules29174240.


Synthetic Receptors for Early Detection and Treatment of Cancer.

Davis F, Higson S Biosensors (Basel). 2023; 13(11).

PMID: 37998127 PMC: 10669836. DOI: 10.3390/bios13110953.


Glycomimetics for the inhibition and modulation of lectins.

Leusmann S, Menova P, Shanin E, Titz A, Rademacher C Chem Soc Rev. 2023; 52(11):3663-3740.

PMID: 37232696 PMC: 10243309. DOI: 10.1039/d2cs00954d.


Galectin-1: A Traditionally Immunosuppressive Protein Displays Context-Dependent Capacities.

Yu X, Qian J, Ding L, Yin S, Zhou L, Zheng S Int J Mol Sci. 2023; 24(7).

PMID: 37047471 PMC: 10095249. DOI: 10.3390/ijms24076501.